Myokardia reports positive results from clinical trial of MYK-491
Category: #health  By Pankaj Singh  Date: 2019-05-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Myokardia reports positive results from clinical trial of MYK-491

Myokardia, a clinical-stage biopharmaceutical company recently presented positive results from its phase 1a clinical trial of MYK-491 dose in healthy volunteers, at the European Society of Cardiology Heart Failure Congress, Greece. Innovated by Myokardia and Sanofi Pharmaceuticals, MYK-491 is an advanced activator molecule and is designed to increase contractility of heart, with minimal effects on myocardial relaxation, reports source.

First-in-human data from the clinical trial of MYK-491 in healthy volunteers has demonstrated the drug to be well tolerated. At higher drug concentrations, MYK -491 increased systolic function (contractility of heart) by 5% to 20% across various echocardiographic parameters with minimal impact on diastolic function.

June Lee, M.D., Executive VP and Chief Development Officer, Myokardia, was reportedly quoted saying that in developing MYK-491, the company targets heart muscle protein to increase contraction along with minimal impact on the heart’s ability to relax & fill itself with oxygenated blood between the beats.

Data from Phase 1a study of MYK-491 in healthy volunteers demonstrated desired effect and the results have been confirmed in Phase 1b study in patients with stable heart failure. The company is looking forward to assessing safety of the drug over several days in multiple-ascending dose study, he added.

As per sources close to the matter, the Phase 1 randomized study was designed to assess tolerability, safety, pharmacokinetics & pharmacodynamics of single-ascending oral doses of MYK-491.  In the study, 64 healthy adult volunteers enrolled to receive single-ascending doses of MYK-491, ranging from 3mg-550mg.

The drug dose was generally well tolerated and no dose-limiting toxicides were observed. The common adverse event reported was headache with no trends of increased adverse events frequency associated with higher concentrations of dose. Pharmacokinetic results indicated the drug may be agreeably received in the form of once- or twice-daily dosing.

           Presently, MYK-491 is being studied in a Phase 2a clinal trial for the treatment of patients with systolic heart failure, the case in which heart does not contract sufficiently to the meet demands of human body.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

XORTX reveals positive results for Phase 2 trial of TMX-049
XORTX reveals positive results for Phase 2 trial of TMX-049
By Pankaj Singh

Type 2 diabetes is a prevailing disease in which cells become unresponsive to insulin while gradually increasing blood sugar. With growing cases of Type 2 diabetes worldwide, pharmaceutical companies are now focusing o...

Emergency Care Partners finalizes its merger with Chicago’s IEMS
Emergency Care Partners finalizes its merger with Chicago’s IEMS
By Pankaj Singh

With rising cases of roadside accidents worldwide, the need for emergency medical facilities have increased considerably in recent years. These facilities offer immediate assistance without any appointments, which make...

Zelegent expands to OSA therapeutics with MISH platform acquisition
Zelegent expands to OSA therapeutics with MISH platform acquisition
By Pankaj Singh

  • MISH Technology stands for Minimally Invasive Suspension of the Hyoid and is a novel pre-clinical product line meant to treat obstructive sleep apnea (OSA).